
    
      This was a Phase 3, open-label, nonrandomized study that consisted of a screening period, an
      open label titration period, and a 52 week, long term, open-label treatment period in
      patients with chronic pain. Patients were eligible to participate in this study if they had
      completed study C33237/3079 (NCT01240863) (these patients are hereafter referred to as
      rollover patients) or if they had not participated in study 3079 (these patients are
      hereafter referred to as either new opioid naÃ¯ve or new opioid experienced patients).
    
  